Clinical Trials Browser

Phase 2/3 × INDUSTRY × Head & Neck × Clear all

NCT04534205 2026-04-15

AHEAD-MERIT

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06295731 2026-03-31

HexAgon-HN

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT06082167 2025-08-17

STELLAR-305

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT05893888 2025-06-15

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06719479 2024-12-05

A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

Nasopharyngeal Carcinoma

NCT04648020 2023-05-31

VOICE

Phase 2/3 Terminated

Head & NeckOther

Head and Neck Neoplasms, Oropharyngeal Neoplasms, Stomatitis, Oral Ulcer, Mucositis

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/3 Terminated

1 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04129320 2022-02-08

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Phase 2/3 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Neoplasms

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Phase 2/3 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00412776 2015-12-23

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Phase 2/3 Terminated

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT00507429 2014-06-09

FACT

Phase 2/3 Terminated

80 enrolled 10 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00261703 2012-05-11

Docetaxel in Head and Neck Cancer

Phase 2/3 Completed

Head and Neck Neoplasms

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT00337532 2010-02-04

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Phase 2/3 Completed

Head and Neck Neoplasms